Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill requires HHS to set annual reference prices for every prescription drug. For drugs available in at least three specified high‑income countries, the reference price is the lowest retail list price among those countries; otherwise HHS sets a price using value and cost factors.
Liberals emphasize direct price relief and access benefits
Relative to its intended legislative type, this bill is a substantive policy change that prescribes an annual HHS-administered reference-pricing regime for prescription drugs, with explicit country-based benchmark rules, broad applicability across federal programs and purchasers, and a statutory civil-penalty enforcement mechanism.
The bill requires HHS to set annual reference prices for every prescription drug.
For drugs available in at least three specified high‑income countries, the reference price is the lowest retail list price among those countries; otherwise HHS sets a price using value and cost factors.
Reference prices cap what federal health program enrollees may pay and require manufacturers to offer drugs at that price to all individuals.
Sweeping nationwide price controls with major implementation challenges and predictable opposition make enactment unlikely unless substantially narrowed or amended.
Relative to its intended legislative type, this bill is a substantive policy change that prescribes an annual HHS-administered reference-pricing regime for prescription drugs, with explicit country-based benchmark rules, broad applicability across federal programs and purchasers, and a statutory civil-penalty enforcement mechanism.
Liberals emphasize direct price relief and access benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize direct price relief and access benefits
Generally strongly supportive, viewing the bill as a direct tool to lower drug prices and expand affordable access.
They will welcome use of international benchmarks and transfer of penalties to NIH for research.
They may press for strong enforcement and rapid HHS implementation.
Cautiously supportive but pragmatic; favors lower drug prices yet worries about implementation, unintended consequences, and costs.
Would look for clear operational rules, transition periods, and legal defensibility.
Support depends on evidence HHS can administer reference pricing without major market disruption.
Likely opposed, viewing the bill as federal price controls and overreach into private markets.
Concerns include harm to innovation, reduced supply, and using foreign prices to set U.S. prices.
They will emphasize property rights, market incentives, and potential negative economic consequences.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Sweeping nationwide price controls with major implementation challenges and predictable opposition make enactment unlikely unless substantially narrowed or amended.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize direct price relief and access benefits
Sweeping nationwide price controls with major implementation challenges and predictable opposition make enactment unlikely unless substanti…
Relative to its intended legislative type, this bill is a substantive policy change that prescribes an annual HHS-administered reference-pricing regime for prescription drugs, with explicit country-based benchmark rules…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.